Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

 
• By Joseph Haas

Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.

Loser concept. Hand drawn failure in business. Unfortunate attempt to hit the target isolated vector illustration.

More from R&D

More from Scrip